Focal vs whole gland brachytherapy boost for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial compares a targeted radiation boost to just the visible tumor versus boosting the whole prostate gland for men with localized prostate cancer. The goal is to see if a more focused approach works as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has not spread beyond the prostate.
- Your cancer is considered intermediate or high risk but still confined to the prostate.
- You have a visible tumor on an MRI scan (PI-RADS score 3-5).
- Your prostate is 60 cc or smaller (or up to 80 cc if you have mild urinary symptoms).
- You have not had prior prostate surgery, HIFU, or pelvic radiation.
- You are able to have an MRI and lie flat for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
This study tests adding a targeted “boost” of HDR (high-dose-rate) internal radiation to the prostate along with standard external beam radiation. It may help improve cancer control while keeping the treatment focused on the area seen on scans and biopsy.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.